Prof. Yongsheng Wang 王永生
Chief Physician, Professor
Department of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Clinical focus on radiation therapy and chemotherapy for tumors. Research interests include the basics and clinical application of biological therapies.
Dr. Wang earned a medical degree from Chongqing Medical University in 1998 and a PhD in Oncology from Sichuan University in 2007. After postdoctoral research in tumor biological therapy, Dr. Wang joined West China Hospital in 2009. Research focuses on biological therapy, with over 20 SCI publications and six patent applications.
Professional roles
- Reviewer, Human Gene Therapy
- Reviewer, Cancer Prevention and Treatment Research
- Editorial Board Member, International Comparison of Scientific and Technological Innovation Capability of Modern Medicine in China
- Contributor, Therapeutic Vaccines
Name order: in Chinese the family name comes first (Wang Yongsheng). Papers usually list the name as Yongsheng Wang or Wang Y.
Selected publications
275 papers on PubMed matched by name and affiliation; 69 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Mater Chem B, 2026 (senior author): Localized hydrogel depots for CAR-T cell therapy in solid tumors: materials design, cellular fitness and translational deployment. PubMed 42900516
- Signal Transduct Target Ther, 2026 (senior author): Carbon nanoparticle-Fe (II) complex for ferroptosis therapy in refractory solid tumors: a phase I trial. PubMed 42816483
- Oncol Lett, 2026 (senior author): Survival prediction in stage II/III rectal cancer: Role of immune-inflammatory biomarkers post neoadjuvant chemoradiotherapy. PubMed 42272772
- Sci Rep, 2026 (senior author): Route-dependent dissemination with conserved blood-tumor barrier ultrastructure in intracranial metastasis models. PubMed 41832153
- Signal Transduct Target Ther, 2026 (senior author): CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies. PubMed 41605906
- Front Oncol, 2026 (senior author): Emerging immunotherapeutic strategies for malignant serous effusions: current evidence and future directions. PubMed 41646434
- Transl Lung Cancer Res, 2025 (senior author): A study protocol of a single-arm, prospective, open-label, non-controlled, phase II study of neoadjuvant BL-B01D1 combined with aumolertinib in resectable stage II-IIIB non-small cell lung cancer patients with EGFR mutation. PubMed 41510386
- Mol Cancer, 2025 (senior author): Next-generation CAR-T cells design: leveraging tumor features for enhanced efficacy. PubMed 41419929
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion